Janney Montgomery Scott LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 40,058 shares of the company’s stock, valued at approximately $16,562,000.
A number of other hedge funds have also made changes to their positions in IDXX. International Assets Investment Management LLC raised its position in shares of IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after acquiring an additional 527,460 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock worth $171,891,000 after purchasing an additional 308,493 shares during the period. Seilern Investment Management Ltd bought a new position in shares of IDEXX Laboratories in the 4th quarter worth about $113,104,000. Finally, Vontobel Holding Ltd. boosted its holdings in shares of IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock valued at $111,229,000 after buying an additional 213,731 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.
Analysts Set New Price Targets
IDXX has been the topic of a number of research reports. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $523.86.
IDEXX Laboratories Trading Up 0.7 %
Shares of NASDAQ IDXX opened at $435.33 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a market cap of $35.65 billion, a price-to-earnings ratio of 41.98, a P/E/G ratio of 3.63 and a beta of 1.36. The business has a fifty day simple moving average of $423.74 and a 200-day simple moving average of $456.35.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.53 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.
Insider Buying and Selling
In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.11% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- Airline Stocks – Top Airline Stocks to Buy Now
- Bloom Energy: Powering the Future With Decentralized Energy
- Dividend Payout Ratio Calculator
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Learn Technical Analysis Skills to Master the Stock Market
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.